Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACB Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

Post Operative Pain Management for ACL Reconstruction

NCT05316168
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine HCl 0.5% Injectable Solution, Dexamethasone, Infiltration between Popliteal Artery and Capsule of the knee (iPACK), Percocet 5Mg-325Mg Tablet
Drug · Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

iPACK for Post-op Pain Following ACL Reconstruction

NCT05498870
View directory record Official record
Conditions
ACL Injury, Post Operative Pain
Interventions
Adductor Canal Block (ACB) Only, Adductor Canal Block (ACB) + iPACK Block
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA)

NCT03703206
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Treating Sleep Apnea in Women Veterans

NCT03377452
View directory record Official record
Conditions
Sleep Apnea
Interventions
Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA), Non-directive sleep apnea education control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Sepulveda, California
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 9, 2026, 2:07 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

NCT02608320
View directory record Official record
Conditions
Healthy
Interventions
Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 9, 2026, 2:07 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

NCT07525375
View directory record Official record
Conditions
Asthma
Interventions
GP MDI, BFF MDI, Placebo MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 11 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Bakersfield, California • Lancaster, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Seltorexant in Healthy Participants

NCT04553042
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 9, 2026, 2:07 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Anterior Femoral and Adductor Canal Nerve Blocks in Peds Knees

NCT06590402
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction, Medial Patellofemoral Ligament Reconstruction
Interventions
Bupivacaine, Dexamethasone in Adductor Canal Block, Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
8 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 9, 2026, 2:07 AM EDT
Withdrawn Not applicable Interventional

ACB + IPACK Block With or Without Local Infiltration in RA-TKA

NCT03840122
View directory record Official record
Conditions
Knee Arthropathy
Interventions
ACB + IPACK block with injection of local anesthetic, ACB + IPACK block without injection
Other
Lead sponsor
University of Louisville
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

NCT07455825
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 9, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials

NCT04115098
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Celecoxib, Naproxen, Meloxicam
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

NCT02345707
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 9, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional

Effectiveness of Exparel Anesthetic Administered by the Surgeon During Knee Surgery

NCT06946368
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block of EXPAREL, Adductor Canal Block (ACB) and Local Local Infiltration Analgesia of EXPAREL, Local Infiltration Analgesia (LIA) of EXPAREL
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

NCT03777761
View directory record Official record
Conditions
Healthy
Interventions
tucatinib, placebo, moxifloxacin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 9, 2026, 2:07 AM EDT
Withdrawn Phase 4 Interventional

Adductor Canal Vs Adductor Canal Plus SPANK Block for Postoperative Pain in Knee Arthroplasty Surgery

NCT04290442
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Anesthesia, Conduction, Acute Pain
Interventions
adductor canal block, SPANK, Ropivacaine
Procedure · Drug
Lead sponsor
Bruce Ben-David
Other
Eligibility
19 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 9, 2026, 2:07 AM EDT
Not listed Not applicable Interventional

Are Adductor Canal Blocks With Bupivacaine and Added Magnesium Better at Managing Post-operative Pain Than Bupivacaine and Added Buprenorphine in Patients Undergoing Same-day Discharge Total Knee Arthroplasty?

NCT05091138
View directory record Official record
Conditions
Post-operative Pain, Acute, Opioid Use
Interventions
Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty, Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants

NCT07652697
View directory record Official record
Conditions
Healthy
Interventions
ABX-002
Drug
Lead sponsor
Autobahn Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

NCT00498615
View directory record Official record
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

NCT04600505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

NCT04757974
View directory record Official record
Conditions
HIV Infections
Interventions
Fostemsavir 600 mg, Fostemsavir 200 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 9, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 9, 2026, 2:07 AM EDT